Related Experiment Video
Updated: Aug 2, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
Dialysis-related amyloidosis
1Department of Medicine, Northwestern University Medical School, Evanston Northwestern Healthcare, Evanston, IL 60201, USA.
Abstract:
Dialysis-related amyloidosis (DRA) is a complication of long-term dialysis and can also be seen in patients with chronical renal failure and on continuous ambulatory peritoneal dyalisis. This review focuses on the chemical modifications of beta(2)-microglobulin that lead to the formation and deposition of beta(2)-amyloid fibrils in periarticular and articular sites which ultimately results in the clinical and radiographic characteristics of this devastating disease. Its most common manifestations are carpal tunnel syndrome, shoulder pain and destructive arthropathy. Treatment of DRA has been directed towards achieving normal serum levels of beta(2)M in end stage renal disease (ESRD) patients which usually results in clinical improvement and delay in disease progression. Medical treatment consists of the use of corticosteroids and nonsteroidal anti-inflammatory drugs. Surgical intervention for carpal tunnel syndrome or spinal cord compression can greatly improve quality of life.
Insights
Dialysis-related amyloidosis (DRA) stems from beta(2)-microglobulin modifications in long-term dialysis patients. Managing beta(2)M levels can improve symptoms and slow disease progression.
Area of Science:
- Nephrology
- Biochemistry
- Rheumatology
Background:
- Dialysis-related amyloidosis (DRA) is a significant complication in patients undergoing long-term dialysis.
- It arises from the accumulation of beta(2)-microglobulin (beta(2)M) amyloid fibrils in joints and surrounding tissues.
- This condition affects patients with chronic renal failure, including those on continuous ambulatory peritoneal dialysis.
Purpose of the Study:
- To review the chemical modifications of beta(2)M leading to amyloid fibril formation.
- To elucidate the pathogenesis of dialysis-related amyloidosis.
- To summarize the clinical manifestations, diagnosis, and treatment strategies for DRA.
Main Methods:
- Literature review focusing on the chemical changes in beta(2)M.
- Analysis of studies detailing the deposition of beta(2)amyloid fibrils.
- Compilation of clinical and radiographic findings associated with DRA.
Main Results:
- Chemical modifications of beta(2)M are central to the formation of beta(2)amyloid.
- Common clinical presentations include carpal tunnel syndrome, shoulder pain, and destructive arthropathy.
- Achieving normal serum beta(2)M levels in end-stage renal disease (ESRD) patients can lead to clinical improvement.
Conclusions:
- Understanding beta(2)M modifications is key to addressing DRA.
- Treatment aims to normalize beta(2)M levels, manage symptoms with corticosteroids or NSAIDs, and consider surgery for specific complications.
- Effective management can improve quality of life for affected patients.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Dialysis
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Nephrotic Syndrome I : Introduction
Diabetic Nephropathy

